Description
Ibutamoren MK-677 20 mg Swiss Pharmaceuticals — ibutamoren (MK-677) from Swiss Pharmaceuticals at 20 mg. Oral GH secretagogue mimicking ghrelin — pulsatile GH release following physiological rhythm rather than bolus injection.
Key Benefits
- Oral GH secretagogue — raises endogenous GH and IGF-1
- Sleep quality, appetite, recovery improvements
- Does not suppress HPTA
- Long-run compound — 3–6 month commitment for full effect
- Water retention common in first month
- Each unit dosed at 20 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 10–25 mg/day, single oral dose pre-bed (sleep benefit) or split. Cycles 3–6 months for full recomposition effect.
How It Works
Ibutamoren, ghrelin-receptor agonist. Triggers endogenous GH pulse release from the pituitary, elevates IGF-1. Mechanism distinct from exogenous HGH — works on the physiological pulse pathway.
Pharmacokinetics
Plasma half-life approximately 24 hours. Single daily dose produces stable GH/IGF-1 elevation.
Potential Side Effects
Water retention first month (resolves). Insulin resistance risk on long runs — monitor fasting glucose. Appetite increase. Mild lethargy in a minority of users.
Cycle & Stacking Guide
3–6 month protocols. Stacks cleanly with SARMs or AAS cycles for recovery amplification. Store pills dry and cool.
Manufacturer Notes
Swiss Pharmaceuticals is a research-compound producer with published batch QC data. Vials ship with tamper-evident caps and date-coded labels.
Storage & Handling
Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.